STUDY OBJECTIVE: To determine the relationship between the antibiotic susceptibility of @entity796 isolated from the sputum of @entity1 with @entity1577 ( @entity1577 ) and the @entity1 's response to parenteral antibiotic administration, we performed a retrospective analysis using data from @entity1 in the placebo arm of a phase 3 trial of @entity2890 solution for inhalation. All @entity1 were chronically infected with @entity796 . Seventy-seven of the 262 @entity1 receiving placebo experienced a pulmonary exacerbation during the trial for which they received therapy with IV @entity2890 and @entity5505 . The susceptibility of the @entity796 isolates to @entity5505 and @entity2890 was determined at trial enrollment by broth microdilution. DESIGN: The clinical response to combination antibiotic therapy was assessed by analyzing differences in spirometry before and after antibiotic administration. The FEV(1) percent predicted at the first visit after the conclusion of antibiotic administration was compared to the FEV(1) percent predicted prior to antibiotic therapy. The results were analyzed both descriptively and by regression analyses. RESULTS: The conditions of 54 @entity1 improved, and those of 9 @entity1 worsened, and in 14 @entity1 there was no change in FEV(1) with antibiotic administration. No correlation was observed between the susceptibility of @entity796 to @entity2890 or @entity5505 and clinical response. Only the three following variables were observed to significantly correlate with FEV(1) after antibiotic treatment on regression analysis: FEV(1) prior to treatment (p < 0.0001); number of days elapsed between the previous FEV(1) measurement and the initiation of IV antibiotic therapy (p < 0.002); and the number of days elapsed between the determination of the minimum inhibitory concentration and the initiation of IV therapy (p < 0.03). No significant trends were observed between the antibiotic susceptibility of @entity796 isolates and treatment outcomes. CONCLUSION: While lack of statistical significance for a trend between bacterial susceptibilities and the response to parenteral antibiotic administration does not mean that no such trend exists, the precision of the confidence intervals allows us to conclude that even if isolate antibiotic susceptibilities affect outcome, the impact would be small and not clinically relevant.

Susceptibility testing of @entity796 isolates and clinical response to parenteral antibiotic administration: lack of association in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2890 :: ('MESH:D014031', 'Chemical') :: ['tobramycin'] @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa', 'P aeruginosa'] @entity5505 :: ('MESH:D002442', 'Chemical') :: ['ceftazidime'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['CF', 'cystic fibrosis']
@entity1577 :: (MESH:D003550,Disease) :: ['cystic fibrosis']
